Prospects and progress of atezolizumab in non-small cell lung cancer.
Identifieur interne : 001240 ( Main/Exploration ); précédent : 001239; suivant : 001241Prospects and progress of atezolizumab in non-small cell lung cancer.
Auteurs : Johan Vansteenkiste [Belgique] ; Els Wauters [Belgique] ; Keunchil Park [Corée du Sud] ; Achim Rittmeyer [Allemagne] ; Alan Sandler [États-Unis] ; Alexander Spira [États-Unis]Source :
- Expert opinion on biological therapy [ 1744-7682 ] ; 2017.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux (immunologie), Anticorps monoclonaux (usage thérapeutique), Anticorps monoclonaux humanisés (MeSH), Carcinome pulmonaire non à petites cellules (anatomopathologie), Carcinome pulmonaire non à petites cellules (immunologie), Carcinome pulmonaire non à petites cellules (traitement médicamenteux), Essais cliniques comme sujet (MeSH), Humains (MeSH), Immunothérapie (MeSH), Marqueurs biologiques tumoraux (métabolisme), Récepteur-1 de mort cellulaire programmée (immunologie), Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (immunologie), Tumeurs du poumon (traitement médicamenteux).
- MESH :
- anatomopathologie : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- immunologie : Anticorps monoclonaux, Carcinome pulmonaire non à petites cellules, Récepteur-1 de mort cellulaire programmée, Tumeurs du poumon.
- métabolisme : Marqueurs biologiques tumoraux.
- traitement médicamenteux : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- usage thérapeutique : Anticorps monoclonaux.
- Anticorps monoclonaux humanisés, Essais cliniques comme sujet, Humains, Immunothérapie.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (MeSH), Biomarkers, Tumor (metabolism), Carcinoma, Non-Small-Cell Lung (drug therapy), Carcinoma, Non-Small-Cell Lung (immunology), Carcinoma, Non-Small-Cell Lung (pathology), Clinical Trials as Topic (MeSH), Humans (MeSH), Immunotherapy (MeSH), Lung Neoplasms (drug therapy), Lung Neoplasms (immunology), Lung Neoplasms (pathology), Programmed Cell Death 1 Receptor (immunology).
- MESH :
- chemical , immunology : Antibodies, Monoclonal, Programmed Cell Death 1 Receptor.
- chemical , metabolism : Biomarkers, Tumor.
- chemical , therapeutic use : Antibodies, Monoclonal.
- chemical : Antibodies, Monoclonal, Humanized.
- drug therapy : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- immunology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- pathology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- Clinical Trials as Topic, Humans, Immunotherapy.
Abstract
INTRODUCTION
Immunotherapy has recently come to the forefront of oncology treatment as a potential means of combating cancer by restoring the body's adaptive cancer-immunity cycle. Atezolizumab is a monoclonal antibody agent that specifically targets programmed death ligand 1 (PD-L1), a key molecule in the cancer-immunity pathway, to block binding to its receptors PD-1 and B7.1. Areas covered: This review covers the role of atezolizumab in the treatment of non-small-cell lung cancer (NSCLC). Several studies have reported promising efficacy in this indication. The phase II FIR and BIRCH studies evaluated atezolizumab monotherapy across different lines of therapy in NSCLC selected by PD-L1 expression status. The randomized POPLAR and OAK trials of atezolizumab versus docetaxel in previously treated NSCLC reported improved efficacy in the atezolizumab arm. Several ongoing studies yet to report data are also described and treatment-related adverse events are discussed. Expert opinion: Clinical trials have shown that atezolizumab has a favorable risk-benefit ratio compared with standard chemotherapy in second-line treatment of non-oncogene-driven advanced NSCLC. Promising response rates and survival over 2 years has been reported in the first-line setting; however, more research is needed in this setting and in evaluating combinatorial strategies to treat NSCLC.
DOI: 10.1080/14712598.2017.1309389
PubMed: 28335643
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prospects and progress of atezolizumab in non-small cell lung cancer.</title><author><name sortKey="Vansteenkiste, Johan" sort="Vansteenkiste, Johan" uniqKey="Vansteenkiste J" first="Johan" last="Vansteenkiste">Johan Vansteenkiste</name><affiliation wicri:level="1"><nlm:affiliation>a Respiratory Oncology Unit, Department of Respiratory Medicine , University Hospitals KU Leuven , Leuven , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a Respiratory Oncology Unit, Department of Respiratory Medicine , University Hospitals KU Leuven , Leuven </wicri:regionArea><wicri:noRegion>Leuven </wicri:noRegion></affiliation></author><author><name sortKey="Wauters, Els" sort="Wauters, Els" uniqKey="Wauters E" first="Els" last="Wauters">Els Wauters</name><affiliation wicri:level="1"><nlm:affiliation>a Respiratory Oncology Unit, Department of Respiratory Medicine , University Hospitals KU Leuven , Leuven , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a Respiratory Oncology Unit, Department of Respiratory Medicine , University Hospitals KU Leuven , Leuven </wicri:regionArea><wicri:noRegion>Leuven </wicri:noRegion></affiliation></author><author><name sortKey="Park, Keunchil" sort="Park, Keunchil" uniqKey="Park K" first="Keunchil" last="Park">Keunchil Park</name><affiliation wicri:level="1"><nlm:affiliation>b Division of Haematology-Oncology, Department of Medicine, Samsung Medical Centre , Sungkyunkwan University School of Medicine , Seoul , Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>b Division of Haematology-Oncology, Department of Medicine, Samsung Medical Centre , Sungkyunkwan University School of Medicine , Seoul </wicri:regionArea><wicri:noRegion>Seoul </wicri:noRegion></affiliation></author><author><name sortKey="Rittmeyer, Achim" sort="Rittmeyer, Achim" uniqKey="Rittmeyer A" first="Achim" last="Rittmeyer">Achim Rittmeyer</name><affiliation wicri:level="1"><nlm:affiliation>c Department of Thoracic Oncology , Lungenfachklinik Immenhausen , Immenhausen , Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>c Department of Thoracic Oncology , Lungenfachklinik Immenhausen , Immenhausen </wicri:regionArea><wicri:noRegion>Immenhausen </wicri:noRegion><wicri:noRegion>Immenhausen </wicri:noRegion><wicri:noRegion>Immenhausen </wicri:noRegion></affiliation></author><author><name sortKey="Sandler, Alan" sort="Sandler, Alan" uniqKey="Sandler A" first="Alan" last="Sandler">Alan Sandler</name><affiliation wicri:level="2"><nlm:affiliation>d Roche-Genentech , South San Francisco , CA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>d Roche-Genentech , South San Francisco , CA </wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Spira, Alexander" sort="Spira, Alexander" uniqKey="Spira A" first="Alexander" last="Spira">Alexander Spira</name><affiliation wicri:level="2"><nlm:affiliation>e US Oncology Thoracic Oncology Program , Virginia Cancer Specialists , Fairfax , VA 22031.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>e US Oncology Thoracic Oncology Program , Virginia Cancer Specialists , Fairfax </wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28335643</idno><idno type="pmid">28335643</idno><idno type="doi">10.1080/14712598.2017.1309389</idno><idno type="wicri:Area/Main/Corpus">001398</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001398</idno><idno type="wicri:Area/Main/Curation">001398</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001398</idno><idno type="wicri:Area/Main/Exploration">001398</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prospects and progress of atezolizumab in non-small cell lung cancer.</title><author><name sortKey="Vansteenkiste, Johan" sort="Vansteenkiste, Johan" uniqKey="Vansteenkiste J" first="Johan" last="Vansteenkiste">Johan Vansteenkiste</name><affiliation wicri:level="1"><nlm:affiliation>a Respiratory Oncology Unit, Department of Respiratory Medicine , University Hospitals KU Leuven , Leuven , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a Respiratory Oncology Unit, Department of Respiratory Medicine , University Hospitals KU Leuven , Leuven </wicri:regionArea><wicri:noRegion>Leuven </wicri:noRegion></affiliation></author><author><name sortKey="Wauters, Els" sort="Wauters, Els" uniqKey="Wauters E" first="Els" last="Wauters">Els Wauters</name><affiliation wicri:level="1"><nlm:affiliation>a Respiratory Oncology Unit, Department of Respiratory Medicine , University Hospitals KU Leuven , Leuven , Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a Respiratory Oncology Unit, Department of Respiratory Medicine , University Hospitals KU Leuven , Leuven </wicri:regionArea><wicri:noRegion>Leuven </wicri:noRegion></affiliation></author><author><name sortKey="Park, Keunchil" sort="Park, Keunchil" uniqKey="Park K" first="Keunchil" last="Park">Keunchil Park</name><affiliation wicri:level="1"><nlm:affiliation>b Division of Haematology-Oncology, Department of Medicine, Samsung Medical Centre , Sungkyunkwan University School of Medicine , Seoul , Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>b Division of Haematology-Oncology, Department of Medicine, Samsung Medical Centre , Sungkyunkwan University School of Medicine , Seoul </wicri:regionArea><wicri:noRegion>Seoul </wicri:noRegion></affiliation></author><author><name sortKey="Rittmeyer, Achim" sort="Rittmeyer, Achim" uniqKey="Rittmeyer A" first="Achim" last="Rittmeyer">Achim Rittmeyer</name><affiliation wicri:level="1"><nlm:affiliation>c Department of Thoracic Oncology , Lungenfachklinik Immenhausen , Immenhausen , Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>c Department of Thoracic Oncology , Lungenfachklinik Immenhausen , Immenhausen </wicri:regionArea><wicri:noRegion>Immenhausen </wicri:noRegion><wicri:noRegion>Immenhausen </wicri:noRegion><wicri:noRegion>Immenhausen </wicri:noRegion></affiliation></author><author><name sortKey="Sandler, Alan" sort="Sandler, Alan" uniqKey="Sandler A" first="Alan" last="Sandler">Alan Sandler</name><affiliation wicri:level="2"><nlm:affiliation>d Roche-Genentech , South San Francisco , CA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>d Roche-Genentech , South San Francisco , CA </wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Spira, Alexander" sort="Spira, Alexander" uniqKey="Spira A" first="Alexander" last="Spira">Alexander Spira</name><affiliation wicri:level="2"><nlm:affiliation>e US Oncology Thoracic Oncology Program , Virginia Cancer Specialists , Fairfax , VA 22031.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>e US Oncology Thoracic Oncology Program , Virginia Cancer Specialists , Fairfax </wicri:cityArea></affiliation></author></analytic><series><title level="j">Expert opinion on biological therapy</title><idno type="eISSN">1744-7682</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (MeSH)</term><term>Biomarkers, Tumor (metabolism)</term><term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term><term>Carcinoma, Non-Small-Cell Lung (immunology)</term><term>Carcinoma, Non-Small-Cell Lung (pathology)</term><term>Clinical Trials as Topic (MeSH)</term><term>Humans (MeSH)</term><term>Immunotherapy (MeSH)</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (immunology)</term><term>Lung Neoplasms (pathology)</term><term>Programmed Cell Death 1 Receptor (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (immunologie)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (MeSH)</term><term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term><term>Carcinome pulmonaire non à petites cellules (immunologie)</term><term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term><term>Essais cliniques comme sujet (MeSH)</term><term>Humains (MeSH)</term><term>Immunothérapie (MeSH)</term><term>Marqueurs biologiques tumoraux (métabolisme)</term><term>Récepteur-1 de mort cellulaire programmée (immunologie)</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (immunologie)</term><term>Tumeurs du poumon (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Programmed Cell Death 1 Receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biomarkers, Tumor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Carcinome pulmonaire non à petites cellules</term><term>Récepteur-1 de mort cellulaire programmée</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Humans</term><term>Immunotherapy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Essais cliniques comme sujet</term><term>Humains</term><term>Immunothérapie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>Immunotherapy has recently come to the forefront of oncology treatment as a potential means of combating cancer by restoring the body's adaptive cancer-immunity cycle. Atezolizumab is a monoclonal antibody agent that specifically targets programmed death ligand 1 (PD-L1), a key molecule in the cancer-immunity pathway, to block binding to its receptors PD-1 and B7.1. Areas covered: This review covers the role of atezolizumab in the treatment of non-small-cell lung cancer (NSCLC). Several studies have reported promising efficacy in this indication. The phase II FIR and BIRCH studies evaluated atezolizumab monotherapy across different lines of therapy in NSCLC selected by PD-L1 expression status. The randomized POPLAR and OAK trials of atezolizumab versus docetaxel in previously treated NSCLC reported improved efficacy in the atezolizumab arm. Several ongoing studies yet to report data are also described and treatment-related adverse events are discussed. Expert opinion: Clinical trials have shown that atezolizumab has a favorable risk-benefit ratio compared with standard chemotherapy in second-line treatment of non-oncogene-driven advanced NSCLC. Promising response rates and survival over 2 years has been reported in the first-line setting; however, more research is needed in this setting and in evaluating combinatorial strategies to treat NSCLC.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28335643</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7682</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>06</Month></PubDate></JournalIssue><Title>Expert opinion on biological therapy</Title><ISOAbbreviation>Expert Opin Biol Ther</ISOAbbreviation></Journal><ArticleTitle>Prospects and progress of atezolizumab in non-small cell lung cancer.</ArticleTitle><Pagination><MedlinePgn>781-789</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14712598.2017.1309389</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Immunotherapy has recently come to the forefront of oncology treatment as a potential means of combating cancer by restoring the body's adaptive cancer-immunity cycle. Atezolizumab is a monoclonal antibody agent that specifically targets programmed death ligand 1 (PD-L1), a key molecule in the cancer-immunity pathway, to block binding to its receptors PD-1 and B7.1. Areas covered: This review covers the role of atezolizumab in the treatment of non-small-cell lung cancer (NSCLC). Several studies have reported promising efficacy in this indication. The phase II FIR and BIRCH studies evaluated atezolizumab monotherapy across different lines of therapy in NSCLC selected by PD-L1 expression status. The randomized POPLAR and OAK trials of atezolizumab versus docetaxel in previously treated NSCLC reported improved efficacy in the atezolizumab arm. Several ongoing studies yet to report data are also described and treatment-related adverse events are discussed. Expert opinion: Clinical trials have shown that atezolizumab has a favorable risk-benefit ratio compared with standard chemotherapy in second-line treatment of non-oncogene-driven advanced NSCLC. Promising response rates and survival over 2 years has been reported in the first-line setting; however, more research is needed in this setting and in evaluating combinatorial strategies to treat NSCLC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vansteenkiste</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>a Respiratory Oncology Unit, Department of Respiratory Medicine , University Hospitals KU Leuven , Leuven , Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wauters</LastName><ForeName>Els</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>a Respiratory Oncology Unit, Department of Respiratory Medicine , University Hospitals KU Leuven , Leuven , Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Keunchil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>b Division of Haematology-Oncology, Department of Medicine, Samsung Medical Centre , Sungkyunkwan University School of Medicine , Seoul , Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rittmeyer</LastName><ForeName>Achim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>c Department of Thoracic Oncology , Lungenfachklinik Immenhausen , Immenhausen , Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandler</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>d Roche-Genentech , South San Francisco , CA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spira</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>e US Oncology Thoracic Oncology Program , Virginia Cancer Specialists , Fairfax , VA 22031.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Biol Ther</MedlineTA><NlmUniqueID>101125414</NlmUniqueID><ISSNLinking>1471-2598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>52CMI0WC3Y</RegistryNumber><NameOfSubstance UI="C000594389">atezolizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Atezolizumab</Keyword><Keyword MajorTopicYN="Y">NSCLC</Keyword><Keyword MajorTopicYN="Y">PD-L1</Keyword><Keyword MajorTopicYN="Y">checkpoint inhibitors</Keyword><Keyword MajorTopicYN="Y">immunotherapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28335643</ArticleId><ArticleId IdType="doi">10.1080/14712598.2017.1309389</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Belgique</li><li>Corée du Sud</li><li>États-Unis</li></country><region><li>Californie</li><li>Virginie</li></region></list><tree><country name="Belgique"><noRegion><name sortKey="Vansteenkiste, Johan" sort="Vansteenkiste, Johan" uniqKey="Vansteenkiste J" first="Johan" last="Vansteenkiste">Johan Vansteenkiste</name></noRegion><name sortKey="Wauters, Els" sort="Wauters, Els" uniqKey="Wauters E" first="Els" last="Wauters">Els Wauters</name></country><country name="Corée du Sud"><noRegion><name sortKey="Park, Keunchil" sort="Park, Keunchil" uniqKey="Park K" first="Keunchil" last="Park">Keunchil Park</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Rittmeyer, Achim" sort="Rittmeyer, Achim" uniqKey="Rittmeyer A" first="Achim" last="Rittmeyer">Achim Rittmeyer</name></noRegion></country><country name="États-Unis"><region name="Californie"><name sortKey="Sandler, Alan" sort="Sandler, Alan" uniqKey="Sandler A" first="Alan" last="Sandler">Alan Sandler</name></region><name sortKey="Spira, Alexander" sort="Spira, Alexander" uniqKey="Spira A" first="Alexander" last="Spira">Alexander Spira</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001240 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001240 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28335643
|texte= Prospects and progress of atezolizumab in non-small cell lung cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28335643" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |